logo
appgoogle
EquityWireNatco Pharma to launch Semaglutide in India Sat; starting price INR 1,290

Natco Pharma to launch Semaglutide in India Sat; starting price INR 1,290

This story was originally published at 10:34 IST on 20 March 2026
Register to read our real-time news.

Informist, Friday, Mar. 20, 2026

 

--Natco Pharma to launch Semaglutide injection in India from Sat at INR 1,290

 

AHMEDABAD – Natco Pharma Ltd. will launch Semaglutide injection in the Indian market under the brand names 'Semanat' and 'Semafull' on Saturday at a price range of INR 1,290 to INR 1,750 per vial depending on the dosage, the company said in a filing with stock exchanges Friday.

 

Natco Pharma received the Central Drugs Standard Control Organisation's approval in February to manufacture and market generic Semaglutide in India for multi-dose vials and pen device based on the clinical comparison study, the filing said. Accordingly, the company will launch the pen device costing INR 4,000 to INR 4,500 per month depending on strength. The pen device is expected to be launched in April, the company said.

 

Semaglutide is used to treat adults with insufficiently controlled type 2 diabetes mellitus. Natco Pharma said its Semaglutide in the vial dosage form is the most affordable GLP-1 in the Indian market as it is around 70% cheaper than the pen device and 90% cheaper than the price of the innovator's brand.

 

For the December quarter, Natco Pharma reported a consolidated profit of INR 1.52 billion and a revenue of INR 6.47 billion. At 1015 IST, shares of the company traded 2.4% higher at INR 960.80 on the National Stock Exchange.  End

 

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Reported by Sunil Raghu

Edited by Tanima Banerjee

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000 

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.

To read more please subscribe

Share this Story:

twitterlinkedinwhatsappmaillinkprint

Related Stories

Premium Stories

Subscribe